View Older Stories View More Recent Stories

Jun 11, 2019 01:00AM OSE Immunotherapeutics Receives U.S. Patent Notice of Allowance for Use of Tedopi® to Treat Brain Metastasis
Jun 11, 2019 01:00AM OSE Immunotherapeutics Receives U.S. Patent Notice of Allowance for Use of Tedopi® to Treat Brain Metastasis
May 28, 2019 02:00AM OSE Immunotherapeutics to Present at 5th Annual Immuno-Oncology: BD&L and Investment Forum
May 28, 2019 02:00AM OSE Immunotherapeutics to Present at 5th Annual Immuno-Oncology: BD&L and Investment Forum
May 22, 2019 12:00PM OSE Immunotherapeutics to Host Key Opinion Leader Meeting on Novel Treatments in Non-Small Cell Lung Cancer
May 22, 2019 12:00PM OSE Immunotherapeutics to Host Key Opinion Leader Meeting on Novel Treatments in Non-Small Cell Lung Cancer
May 20, 2019 12:00PM OSE Immunotherapeutics Receives Notice of Allowance for New U.S. Patent Protecting Anti-IL-7 Receptor Antagonist OSE-127
May 20, 2019 12:00PM OSE Immunotherapeutics Receives Notice of Allowance for New U.S. Patent Protecting Anti-IL-7 Receptor Antagonist OSE-127
Apr 11, 2019 12:00PM OSE Immunotherapeutics Announces Publication on Anti-IL-7 Receptor Antagonist, OSE-127, in The Journal of Clinical Investigation
Apr 11, 2019 12:00PM OSE Immunotherapeutics Announces Publication on Anti-IL-7 Receptor Antagonist, OSE-127, in The Journal of Clinical Investigation
Apr 9, 2019 01:00PM OSE Immunotherapeutics Announces Issuance of Canadian Patent and Notice of Allowance of U.S. Patent Protecting CD28-Antagonist Immunotherapy FR104
Apr 9, 2019 12:00PM OSE Immunotherapeutics Announces Issuance of Canadian Patent and Notice of Allowance of U.S. Patent Protecting CD28-Antagonist Immunotherapy FR104
Apr 2, 2019 12:00PM OSE Immunotherapeutics Presents New Clinical and Preclinical Data on its Immuno-Oncology Portfolio at AACR 2019
Apr 2, 2019 12:00PM OSE Immunotherapeutics Presents New Clinical and Preclinical Data on its Immuno-Oncology Portfolio at AACR 2019
Mar 28, 2019 01:00PM OSE Immunotherapeutics Reports 2018 Financial Results and Business Update
Mar 28, 2019 01:00PM OSE Immunotherapeutics Reports 2018 Financial Results and Business Update
Mar 26, 2019 01:00PM OSE Immunotherapeutics Announces New Research Collaboration with Léon Bérard Cancer Center to Use Artificial Intelligence Technologies to Identify Novel Immuno-Oncology Targets
Mar 26, 2019 01:00PM OSE Immunotherapeutics Announces New Research Collaboration with Léon Bérard Cancer Center to Use Artificial Intelligence Technologies to Identify Novel Immuno-Oncology Targets
Mar 7, 2019 12:00PM OSE Immunotherapeutics Presents its Novel Bispecific Checkpoint Inhibitor Platform, Targeting PD-1 and Innovative Targets
Mar 7, 2019 12:00PM OSE Immunotherapeutics Presents its Novel Bispecific Checkpoint Inhibitor Platform, Targeting PD-1 and Innovative Targets at the 2019 World Immunotherapy Congress
Mar 5, 2019 12:12PM OSE Immunotherapeutics Announces Clinical Trial Authorization for a Phase 1 by two Health Agencies (France and Belgium) to Evaluate the Selective SIRPα antagonist BI 765063* under Development in Coll
Mar 5, 2019 12:03PM OSE Immunotherapeutics Announces Clinical Trial Authorization for a Phase 1 by two Health Agencies (France and Belgium) to Evaluate the Selective SIRPα antagonist BI 765063*...
Feb 28, 2019 01:00AM OSE Immunotherapeutics to Present New Clinical and Preclinical Data on its Immuno-Oncology Portfolio at AACR 2019
Feb 28, 2019 01:00AM OSE Immunotherapeutics to Present New Clinical and Preclinical Data on its Immuno-Oncology Portfolio at AACR 2019
Feb 7, 2019 12:00PM OSE Immunotherapeutics and Servier Announce First Option Within Global License Agreement Exercised for Further Clinical Development and Potential Commercialisation of OSE-127 in Autoimmune Diseases
Feb 7, 2019 12:00PM OSE Immunotherapeutics  and Servier Announce First Option Within Global License Agreement Exercised for Further Clinical Development and Potential Commercialisation of OSE-127 in Autoimmune Diseases
Jan 15, 2019 12:00PM OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi® to Treat Brain Metastasis
Jan 15, 2019 12:00PM OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi® to Treat Brain Metastasis
Jan 3, 2019 12:00PM OSE Immunotherapeutics to Present at Biotech Showcase™ 2019 Conference
Jan 3, 2019 12:00PM OSE Immunotherapeutics to present at Biotech Showcase™ 2019 Conference
Dec 20, 2018 12:00PM OSE Immunotherapeutics Announces First Healthy Volunteers Dosed in Phase 1 Clinical Trial of OSE-127
Dec 20, 2018 12:00PM OSE Immunotherapeutics Announces First Healthy Volunteers Dosed in Phase 1 Clinical Trial of OSE-127
Dec 17, 2018 12:00PM OSE Immunotherapeutics Appoints Julien Perrier Chief Commercial Officer
Dec 17, 2018 12:00PM OSE Immunotherapeutics Appoints Julien Perrier Chief Commercial Officer
Dec 10, 2018 12:00PM OSE Immunotherapeutics Invited to Present Mechanistic Data on Clinical Stage Anti-Interleukin-7 Receptor Antagonist OSE-127 at Two International Scientific Conferences
Dec 10, 2018 12:00PM OSE Immunotherapeutics Invited to Present Mechanistic Data on Clinical Stage Anti-Interleukin-7 Receptor Antagonist OSE-127 at Two International Scientific Conferences
Nov 26, 2018 12:00PM OSE Immunotherapeutics Receives Belgian Authorization for a Phase 1 Clinical Trial to Evaluate Anti-IL-7 Receptor Antagonist OSE-127
Nov 26, 2018 12:00PM OSE Immunotherapeutics Receives Belgian Authorization for a Phase 1 Clinical Trial to Evaluate Anti-IL-7 Receptor Antagonist OSE-127
Nov 20, 2018 02:00AM OSE Immunotherapeutics and Oncology Physician Network GERCOR Announce Initiation of Phase 2 Clinical Trial to Evaluate Tedopi® in Combination with Opdivo® (nivolumab) in Pancreatic Cancer
Nov 20, 2018 02:00AM OSE Immunotherapeutics and Oncology Physician Network GERCOR Announce Initiation of Phase 2 Clinical Trial to Evaluate Tedopi® in Combination with Opdivo® (nivolumab) in Pancreatic Cancer
Nov 2, 2018 03:00AM OSE Immunotherapeutics Regains Worldwide Rights to its CD28 antagonist FR104 from Janssen Biotech
Nov 2, 2018 03:00AM OSE Immunotherapeutics Regains Worldwide Rights to its CD28 antagonist FR104 from Janssen Biotech
Oct 30, 2018 01:00PM OSE Immunotherapeutics Presents Selective SIRP-alpha antibodies: OSE-172, a next-generation myeloid checkpoint inhibitor at the World Immunotherapy Congress
Oct 30, 2018 01:00PM OSE Immunotherapeutics Presents Selective SIRP-alpha antibodies: OSE-172, a next-generation myeloid checkpoint inhibitor at the World Immunotherapy Congress
Oct 29, 2018 03:00AM OSE Immunotherapeutics Announces Publication in Nature Communications on Anti-IL-7 Receptor Antagonist (OSE-127)
Oct 29, 2018 02:00AM OSE Immunotherapeutics Announces Publication in Nature Communications on Anti-IL-7 Receptor Antagonist (OSE-127)
Oct 10, 2018 12:00PM OSE Immunotherapeutics and Oncology Physician Network GERCOR Announce Submission of Investigational New Drug Application to Evaluate Tedopi® in Combination with Nivolumab in Pancreatic Cancer
Oct 10, 2018 12:00PM OSE Immunotherapeutics and Oncology Physician Network GERCOR Announce Submission of Investigational New Drug Application to Evaluate Tedopi® in Combination with Nivolumab in Pancreatic Cancer
Oct 1, 2018 12:00PM OSE Immunotherapeutics to Present at the 18th Annual Biotech in Europe Investor Forum
Oct 1, 2018 12:00PM OSE Immunotherapeutics to Present at the 18th Annual Biotech in Europe Investor Forum
View More Recent Stories View Older Stories